Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Bolsters Position In MS Now That Tecfidera Is A Blockbuster

This article was originally published in The Pink Sheet Daily

Executive Summary

The spec pharma’s latest MS offering surpasses $1 billion in sales as roll-out begins in Europe and focuses some of its resources toward its budding hemophilia franchise.

You may also be interested in...



Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix

Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.

Biogen Leans On Plegridy To Help Extend The Life Of Avonex

The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.

Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri

Biogen Idec announced Feb.6 that it will pay $3.25 billion to its partner Elan for full rights to the multiple sclerosis drug Tysabri. The deal was not a surprise to Biogen investors, but it leaves Elan with a war chest of cash and virtually no commercial assets.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel